# Clinical Trials Data ALK - Document 9

# Attention Bias Modification Treatment for Anxious Youth

## Clinical Trial: https://clinicaltrials.gov/study/NCT01979263

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Diagnosis on Anxiety Disorders Interview Schedule for Diagnostic and Statistical Manual-IV Child and Parent versions of Separation Anxiety Disorder, Social Phobia, Specific Phobia, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder\n\* Age 7 to 17\n\nExclusion Criteria:\n\n\* Posttraumatic stress disorder or primary diagnosis of major depressive disorder\n\* Seizure disorder\n\* Current treatment with psychotropic medication\n\* Multiple chronic learning disabilities and/or conduct problems",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "7 Years",  
"stdAges": [  
"CHILD"  
]

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, the patient's eligibility is not determined by the presence of an ALK gene mutation. The criteria focus on psychiatric diagnoses, age, certain exclusionary mental health conditions and treatments, and chronic learning or conduct issues.  
  
The trial:  
- Includes patients who have been diagnosed with certain anxiety disorders.  
- Requires participants to be between the ages of 7 and 17.  
- Excludes individuals with PTSD, primary major depressive disorder, seizure disorders, current treatment with psychotropic medication, or significant learning or conduct problems.  
  
Therefore, the presence of an ALK gene mutation is not relevant to the eligibility criteria for this particular clinical trial. If a patient fits within the age range and diagnostic categories specified and does not meet any of the exclusion criteria, they may be considered eligible, regardless of any ALK gene mutation.